Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Natural killer and cytotoxic CD8+ T cells are major players during antitumor immunity. They express NKG2D, an activating receptor that promotes tumor elimination through recognition of the MHC class I chain-related proteins A and B (MICA and MICB). Both molecules are overexpressed on a great variety of tumors from different tissues, making them attractive targets for immunotherapy. However, tumors shed MICA and MICB, and the soluble forms of both (sMICA and sMICB) mediate tumor-immune escape. Some reports indicate that anti-MICA antibodies (Ab) can promote the restoration of antitumor immunity through the induction of direct antitumor effects (antibody-dependent cell-mediated cytotoxicity, ADCC) and scavenging of sMICA. Therefore, we reasoned that an active induction of anti-MICA Ab with an immunogenic protein might represent a novel therapeutic and prophylactic alternative to restore antitumor immunity. Methods: We generated a highly immunogenic chimeric protein (BLS-MICA) consisting of human MICA fused to the lumazine synthase from Brucella spp (BLS) and used it to generate anti-MICA polyclonal Ab (pAb) and to investigate if these anti-MICA Ab can reinstate antitumor immunity in mice using two different mouse tumors engineered to express MICA. We also explored the underlying mechanisms of this expected therapeutic effect. Results: Immunization with BLS-MICA and administration of anti-MICA pAb elicited by BLS-MICA significantly delayed the growth of MICA-expressing mouse tumors but not of control tumors. The therapeutic effect of immunization with BLS-MICA included scavenging of sMICA and the anti-MICA Ab-mediated ADCC, promoting heightened intratumoral M1/proinflammatory macrophage and antigen-experienced CD8+ T cell recruitment. Conclusions: Immunization with the chimeric protein BLS-MICA constitutes a useful way to actively induce therapeutic anti-MICA pAb that resulted in a reprogramming of the antitumor immune response towards an antitumoral/proinflammatory phenotype. Hence, the BLS-MICA chimeric protein constitutes a novel antitumor vaccine of potential application in patients with MICA-expressing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For example, hypoxia promotes the secretion of CCL28 by tumor cells in a HIF-1α-dependent manner, which enhances recruitment of CCR10+ T reg cells to the tumor site, suppressing the functions of cytotoxic T cells and promoting tumor growth (Fig. 2C) [81,82].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
Cerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Salih, H. R., Antropius, H., Gieseke, F., Lutz, S. Z., Kanz, L., Rammensee, H.-G., & Steinle, A. (2003) · Blood · doi:10.1182/blood-2003-01-0019 · Cited by 541
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
Ferrari de Andrade, L., Tay, R. E., Pan, D., Luoma, A. M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K. F., Harvey, C. J., et al. (2018) · Science · doi:10.1126/science.aao0505 · Cited by 459
Ashiru, O., Boutet, P., Fernández-Messina, L., Agüera-González, S., Skepper, J. N., Valés-Gómez, M., & Reyburn, H. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1688 · Cited by 421
Tumor-Associated MICA Is Shed by ADAM Proteases
Waldhauer, I., Goehlsdorf, D., Gieseke, F., Weinschenk, T., Wittenbrink, M., Ludwig, A., Stevanovic, S., Rammensee, H.-G., & Steinle, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6768 · Cited by 375
Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma
Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D., Steinle, A., Ferrone, S., & Pistoia, V. (2004) · Neoplasia · doi:10.1593/neo.04316 · Cited by 264
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
Jinushi, M., Takehara, T., Tatsumi, T., Kanto, T., Groh, V., Spies, T., Kimura, R., Miyagi, T., Mochizuki, K., Sasaki, Y., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10966 · Cited by 244
Zwirner, N. W., Fernández-Viña, M. A., & Stastny, P. (1997) · Immunogenetics · doi:10.1007/s002510050339 · Cited by 236
Self-citationSumitran-Holgersson, S., Wilczek, H. E., Holgersson, J., & Soderstrom, K. (2002) · Transplantation · doi:10.1097/00007890-200207270-00019 · Cited by 204
Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells
Wang, B., Wang, Q., Wang, Z., Jiang, J., Yu, S.-C., Ping, Y.-F., Yang, J., Xu, S.-L., Ye, X.-Z., Xu, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2563 · Cited by 198
Zwirner, N. W., Marcos, C. Y., Mirbaha, F., Zou, Y., & Stastny, P. (2000) · Human Immunology · doi:10.1016/s0198-8859(00)00162-2 · Cited by 184
Self-citationJinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168
Watson, N. F. S., Spendlove, I., Madjd, Z., McGilvray, R., Green, A. R., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.21510 · Cited by 166
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
Zhang, J., Basher, F., & Wu, J. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00097 · Cited by 146
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Zingoni, A., Fionda, C., Borrelli, C., Cippitelli, M., Santoni, A., & Soriani, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01194 · Cited by 125
NF-κB Regulates Expression of the MHC Class I-Related Chain A Gene in Activated T Lymphocytes
Molinero, L. L., Fuertes, M. B., Girart, M. V., Fainboim, L., Rabinovich, G. A., Costas, M. A., & Zwirner, N. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5583 · Cited by 116
Self-citationIraolagoitia, X. L. R., Spallanzani, R. G., Torres, N. I., Araya, R. E., Ziblat, A., Domaica, C. I., Sierra, J. M., Núñez, S. Y., Secchiari, F., Gajewski, T. F., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502291 · Cited by 107
Self-citationFuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A., & Zwirner, N. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4606 · Cited by 105
Self-citationGoldbaum, F. A., Leoni, J., Wallach, J. C., & Fossati, C. A. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.8.2141-2145.1993 · Cited by 101
Self-citationZingoni, A., Cecere, F., Vulpis, E., Fionda, C., Molfetta, R., Soriani, A., Petrucci, M. T., Ricciardi, M. R., Fuerst, D., Amendola, M. G., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402643 · Cited by 100
MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer
Cho, H., Chung, J., Kim, S., Braunschweig, T. A., Kang, T. H., Kim, J., Chung, E. J., Hewitt, S. M., & Kim, J.-H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-957 · Cited by 95
Zylberman, V., Craig, P. O., Klinke, S., Braden, B. C., Cauerhff, A., & Goldbaum, F. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312035200 · Cited by 93
Self-citationFionda, C., Malgarini, G., Soriani, A., Zingoni, A., Cecere, F., Iannitto, M. L., Ricciardi, M. R., Federico, V., Petrucci, M. T., Santoni, A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201426 · Cited by 79
Upregulation of MICA on high-grade invasive operable breast carcinoma.
Madjd, Z., Spendlove, I., Moss, R. S., Bevin, S., Pinder, S. E., Watson, N. F., Ellis, I. O., & Durrant, L. G. (2007) · PubMed Central · Cited by 74
Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides
Laplagne, D. A., Zylberman, V., Ainciart, N., Steward, M. W., Sciutto, E., Fossati, C. A., & Goldbaum, F. A. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20248 · Cited by 70
Self-citationSconocchia, G., Spagnoli, G. C., Principe, D. D., Ferrone, S., Anselmi, M., Wongsena, W., Cervelli, V., Schultz‐Thater, E., Wyler, S. F., Carafa, V., et al. (2009) · Neoplasia · doi:10.1593/neo.09296 · Cited by 70
A Polymeric Bacterial Protein Activates Dendritic Cells via TLR4
Berguer, P. M., Mundiñano, J., Piazzón, I., & Goldbaum, F. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2366 · Cited by 62
Self-citationMICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
Zingoni, A., Vulpis, E., Cecere, F., Amendola, M. G., Fuerst, D., Saribekyan, T., Achour, A., Sandalova, T., Nardone, I., Peri, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00926 · Cited by 50
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Graff, J. N., Li, Z., & Wu, J. D. (2017) · Science Advances · doi:10.1126/sciadv.1602133 · Cited by 40
Targets of Protective Tumor Immunity
Dranoff, G. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04938.x · Cited by 36
Du, C., Bevers, J. J., Cook, R., Lombana, T. N., Rajasekaran, K., Matsumoto, M. L., Spiess, C., Kim, J. M., & Ye, Z. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0687-9 · Cited by 35
Ribeiro, C. H., Kramm, K., Gálvez‐Jirón, F., Pola-Véliz, V., BUSTAMANTE, M., Contreras, H. R., Sabag, A., Garrido‐Tapia, M., Hernández, C., ZÚÑIGA, R., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4510 · Cited by 33
Chen, F., Zhang, G., Cao, Y., Hessner, M. J., & See, W. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.08.018 · Cited by 29
Spallanzani, R. G., Dalotto‐Moreno, T., Iraolagoitia, X. L. R., Ziblat, A., Domaica, C. I., Avila, D. E., Rossi, L. E., Fuertes, M. B., Battistone, M. A., Rabinovich, G. A., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1483-x · Cited by 23
Self-citation
Cited by
Role of hypoxia in the tumor microenvironment and targeted therapy
Chen, G., Wu, K., Li, H., Xia, D., & He, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961637 · Cited by 346
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Leveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 165
Self-citationNatural killer cells in cancer immunotherapy
Wang, D., Dou, L., Sui, L., Xue, Y., & Xu, S. (2024) · MedComm · doi:10.1002/mco2.626 · Cited by 58
Metadata
- Authors
- Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., Gilio, N., Almada, E., Lauche, C., Pardo, R., Domaica, C. I., Fuertes, M. B., Madauss, K. P., Hance, K. W., Gloger, I. S., Zylberman, V., Goldbaum, F. A., & Zwirner, N. W.
- Affiliations
- Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
- Experimental Medicine and Biology Institute (AR)
- Inmunova, Buenos Aires, Argentina
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Fundación Instituto Leloir (AR)
- Universidad de Buenos Aires (AR)
- Corresponding author
- Zwirner, Norberto Walter
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-06
- Volume
- 8
- Issue
- 1
- Pages
- e000233
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7282397
- OpenAlex
- W3033899855
- Cited by
- 29
- References
- 45
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 7
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- GlaxoSmithKline
- Fundación Williams
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Sapienza Università di Roma
- Universidad de Buenos Aires (CONICET)
- Fundación René Barón
- Agencia Nacional de Promoción Científica y Tecnológica (CONICET)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- mica, MICB, anti-MICA antibodies, fusion protein, lumazine synthase, Brucella, antitumor immunity, tumor immune evasion, soluble MICA, antibody-dependent cellular cytotoxicity, NKG2D, CD8+ T cells, M1 macrophages, cancer vaccines, immunogenic proteins
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Urinary Bladder Neoplasms, Brucella, Female, Lymphoma, Male, Mice, Inbred C57BL, Multienzyme Complexes, Recombinant Fusion Proteins, Tumor Cells, Cultured, Histocompatibility Antigens Class I, Mice, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.